

Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF	ATTY. DOCKET	SERIAL NO.:				
COMMERCE, PATENT AND TRADEMARK OFFICE	NO.: STRM 8432W1	10/511,818				
•		U.S. National Phase				
		International Appln. N				
		PCT/US03/12602				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT See Attached (33 pages)	APPLICANT: Meir Strahilevitz					
(Use several sheets if necessary)	Filing Date: July 7, 2005 Group: 1644					

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number												Patent Issue Date OR US App. Pub. Date OR US Non-Published Application Filing Date	Name	
175	US	5	1	6	0	4	8	3						Nov. 3, 1992	Postlethwaite et al	
	US															
	ÜS		\top	Г				П				П				
	US	1	\top			Π		Г			Ī				 	
	US		\top				Γ			Γ		Г				

FOREIGN PATENT DOCUMENTS

Examiner					Translation					
Initial	Document Number				er	Date	Country	Yes	No	
	Т			Г						
					Г	T-				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DOC	Dalum I et al, Therapeutic Antibodies Elicited by Immunization Against TNF-ALPHA, Nature Biotechnology, Nature Publishing, US, Vol. 17, no. 7, 1999, pp.666-669
(431)	Nagahira K et al, Humanization of a mouse neutralizing momoclonal antibody against tumor necrosis factor-alpha (TNF-alpha), Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, Vol. 222, no. 1-2, 1999, pp. 83-92
	Ten hagen T L M et al; A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor- 'alphal And cytotoxic agents", Advanced Drug Delivery Reviews 1997, Netherlands, Vol. 24, no. 2-3, pp. 245-256

EXAMINER DATE	CONSIDERED 12/207

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

DEC 2 2 2005

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: STRM 8432W1 SERIAL NO.: 10/511,818

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

See Attached

Filing Date: July 7, 2005

APPLICANT: Meir Strahilevitz

Group: 1644

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number										Kind Code (click here)	Patent Issue Date OR US App. Pub. Date OR US Non-Published Application Filing Date	. Name
<u> </u>	US		3	4	5	3	1	9	4			Α	7-1-69	Bennett et al
1	US		4	3	7	5	4	1	4			Α	3-1-83	Strahilevitz
	US		4	8	1	3	9	2	4			Α	3-21-89	Strahilevitz
	US		4	6	2	7	9	1	5			Α	12-9-86	Kuroda
	US		5	7	5	3	2	2	7			Α	5-19-98	Strahilevitz
	US		6	0	3	9	9	4	6			Α	3-21-2000	Strahilevitz
	US		6	0	4	6	2	2	5			Α	4-4-2000	Maddock
	US		6	2	3	1	5	თ	6			A1	5-15-01	Lentz
	US		6	2	5	1	3	တ	4			A1	6-26-01	Nillson
A	US		6	2	6	4	6	2	3			A1	7-24-01	Strahilevitz

FOREIGN PATENT DOCUMENTS

Examiner										Transl	ation
Initial	D	ocu	me	nt N	Vun	nbe	r	Date	Country	Yes	No
((()	9	6	3	7	5	1	6	11/28/1996	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ahonen et al., Acta Oncologica (1993) Vol. 32, Mos. 7/8, pp. 723-27
P. Aukrust et al., (8/10/99), Vol 100(6), pp. 6/14-20
N. M. Bakry et al., Infec. Immunol., (1997), Vol 65 (6) pp. 2225-32
E. A. Bayer and M. Wilchek, J. of Mol. Rec., (1990), Vol. 3(3), pp. 102-07
B. G. Beatty et al., Cancer Res 49, (March 15, 1989), pp. 1587-1594
L. M. Biasucci et al., Circulation, (April 27, 1999), Vol. 99 (16) pp. 2079-84
C. Botti et al., Int. J. Biol. Markers, (1998), Vol. 13 (2), pp. 51-69
G. Caligiuri et al., Circulation, (September 5, 2000), Vol. 102 (10) pp. 1114-19
J. A. Carrasquille et al., Cancer Treatment Reports, (January 1984), Vol. 68, No. 1, pp. 317-328
L. J. Corpfield and M. A. Sills, Eur. J. Pharmacol., (Sept 4, 1991), Vol. 202(1) pp. 113-
C. M. Eppler et al., J. Biol. Chem., (August 5, 1992), Vol. 267 (22), pp. 15603-12
8. Fretier et al., J. Leukoc. Biol., (Feb. 2002), Vol. 71(2), pp. 289-94
C. Galanos, in Encyclopedia of Immunology, I.M. Roitt and P.J. Delves eds., Academic Press, (1992), pp. 500-01

u h

12/12/07

37 CFV (b)(5)

FORM PTO-1449 U.S. DEPARTMENT OF MMERCE, PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO.: STRM 8432W1 SERIAL NO.: 10/511,818

INFORMATION DISCLOSURE STATEMENT BY APPLICANT See Attached

(Use several sheets if necessary)

Filing Date: July 7, 2005

APPLICANT: Meir Strahilevitz

Group: 1644

	M. Garkavij et al., Cancer Research (Suppl.), (December 1, 1995), Vol. 55, pp. 5874s – 5880s
	J. Goding et al., J. Immunological Methods, (1978), Vol. 20, pp. 241-53
	B. A. Goff et al., Br. J. Caneer, (1994), Vol. 70, pp. 474-480
	D. A. Goodwin, Antibody Immunoconjugates and Radiopharmaceuticals, (1991), Vol. 4, (4), pp. 427-434
•	2. K. Hansson, Circulation, (2002) Vol. 106, pp. 1599-1601
442	E. Harlow and D. Lane: "Antibodies, A Laboratory Manual", Cold Spring Harbor Laboratory (Pub. 1988), pp. 328-9, 340-1, 511, 513, 516-27, 547-52
	K. Hashimoto et al., Biochim Biophys Acta, (April 25, 1986) Vol. 856 (3), pp. 556-65
ml	K. E. Hellstrom and I. Hellstrom, Encyclopedia of Immunology, I.M. Roitt and P.J. Delves Eds., Academic Press (1992), pp. 1530-1531.
YN3/	R.B. Herberman; Encyclopedia of Immunology, I. M. Roitt and P.J. Delves, Eds. Academic Press (1992), pp. 1013-15
	L. M. Hinman et al., Cancer Research, (July 15, 1993), Vol 53, pp. 3326-3342
	C. Ingvar et al., Nucl. Med., (1989), Vol. 30, pp. 1224-34
	H. P. Kalofonos et al., The Journal of Nuclear Medicine, (Nov. 1990), Vol. 31, No 11, pp. 1791-1796
	J. Karvonen et al., Sirculation, (2003), Vol. 108, pp. 2107-2112
	H. Koukkunen et al., Ann. Med., (2001), Vol. 33, pp. 37-47
	W-H. Lee et al., Int. J. Cardiol., (8ept-Oct 2001), Vol. 80 (2-3), pp. 135-42
	W-H. Lee et al., Cardiology, (1999), Vol. 92 (1), pp. 11-16
	M. R. Lentz, Therapeutic Apheresis, (1999), Vol. 3(1), pp. 40-49
	C. N. Lieske et al., Immunol. Lett. (Feb. 1992), Vol. 31(2), pp. 117-22
	E. Lindmark et al., JAMA (Nov. 7, 2001), Vol. 286(17), pp. 2107-13
	G. Liúzzo et al., Circulation, (Nov. 23, 1999), Vol. 100(21), pp. 2135-39
	C. Lollo et al., Nuclear Medicine Communications (1994), Vol. 15, pp. 483-491
Im.	M. Londei, in Encyclopedia of Immunology, I.M. Roitt and P.J. Delves Eds., Academic Press (1992), pp. 443-445
	L. K. Mahal et al., Science, (May 16, 1997), Vol. 276, pp. 1125-1128
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 140 No 1, part 1, pp. 30-39
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 110 No 1, part 1, pp. 30-39 R. Maron et al., Circulation, (2002), Vol. 106, pp. 1708-1715
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 110 No 1, part 1, pp. 30-39 R. Maron et al., Circulation, (2002), Vol. 106, pp. 1708-1715 A. Mazzone et al., Atherosclerosis, (1999), Vol. 145, pp. 369-74
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 110 No 1, part 1, pp. 30-39 R. Maron et al., Circulation, (2002), Vol. 106, pp. 1708-1715
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 110 No 1, part 1, pp. 30-39 R. Maron et al., Circulation, (2002), Vol. 106, pp. 1708-1715 A. Mazzone et al., Atherosclerosis, (1999), Vol. 145, pp. 369-74 D. G. McNeel et al., J. Urol. (Nov. 2000), Vol. 164, No.5, pp. 1825-1829 J. L. Middlebrook and R. B. Dorland, Microbiological Rev., (Sept. 1984), Vol. 48(3), pp. 199-221
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 110 No 1, part 1, pp. 30-39 R. Maron et al., Circulation, (2002), Vol. 106, pp. 1708-1715 A. Mazzone et al., Atherosclerosis, (1999), Vol. 145, pp. 369-74 D. G. McNeel et al., J. Urol. (Nov. 2000), Vol. 164, No.5, pp. 1825-1829 J. L. Middlebrook and R. B. Dorland, Microbiological Rev., (Sept. 1984), Vol. 48(3), pp. 199-221 J. Muller et al., Circulation, (2000), Vol. 101, pp. 385-391
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 110 No 1, part 1, pp. 30-39 R. Maron et al., Circulation, (2002), Vol. 106, pp. 1708-1715 A. Mazzone et al., Atherosclerosis, (1999), Vol. 145, pp. 369-74 D. G. McNeel et al., J. Urol. (Nov. 2000), Vol. 164, No.5, pp. 1825-1829 J. L. Middlebrook and R. B. Dorland, Microbiological Rev., (Sept. 1984), Vol. 48(3), pp. 199-221

considered refs
lack title (37 LFN 1.98 (b)(5) tow

ets considered

ORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: STRM 8432W1 SERIAL NO.: 10/511,818

INFORMATION DISCLOSURE STATEMENT BY APPLICANT See Attached

(Use several sheets if necessary)

Filing Date: July 7, 2005

APPLICANT: Meir Strahilevitz

Group: 1644

bacco , bortions

whous

No tith

	D. E. Newby and K. A. Fox, Br Med Bull, (2001), Vol. 59, pp. 69-87
	A. Otte et al., The Lancet, (Feb. 7, 1998), Vol. 351, pp. 417-18
	G. Paganelli-et al., Int J. Cancer Suppl. 2, (1988), pp. 121-125
	V-Pasceri and E.T.H. Yeh, Circulation (1999), Vol. 100, pp. 2124-2126
MUI	Pharmacia LKB Biotechnology, Pub. #18-1022-29, "Affinity Chromatography: Principles & Methods" (1991), 114 pages, particularly pp. 47-52
	J:-Rlutzky, AM. J. Cardiol., (Oct. 18, 2001), Vol. 88 (8A), pp. 10K-15K
	L. E. Rabbani, New England J. Med, (Oct. 4, 2001), Vol. 345(14), pp. 1057-59
	C. C. Raggi et al., Clin. Cancer Res., (Feb. 8, 2002), Vol. 8 (2), pp. 419-427
	S. A. Rosenberg et al., Science, (Sept. 1986), Vol. 233(4770), pp. 1318-21
	F. A. Salinas and M. G. Hanna, Jr., Eds. Contemporary Topics in Immunobiology, Vol. 15, harmune Complexes and Human Cancer, Plenum Press, (1985), pp. 1-280
	I. Schipake et al, J. Am. College of Cardiol, (2001), Vol. 38, No 1, pp. 178-183
COPPORT	A.H.G.J. Schrijvers et al, Cancer Research(53),(September 15, 1993), pp. 4383-4390, Immune Complexes and Plasma Exchange in Cancer Patients
	B. Serrou and C. Rosenfeld, Eds. Elsvier/ North-Holland Biomedical Press, (1981), pp. 1344
	Sievers et al., Blood Vol. 93(11), (June 1, 1999), pp. 3678-3684
	S. D. Singh-and C. G. Booth, J. Immunol. Methods (2002), Vol. 260 (1-2) pp. 149-56
	D. A. Smith et al., Circulation, (Aug. 14, 2001), Vol. 104(7) pp. 746-9
	P. A. Sobotka et al., Free Radical Biology and Med., (1993), Vol. 14, pp. 643-647
	H. Tashiro et al., Coronary Artery Disease, (March 1997), Vol. 8 (3-4), pp. 143-147
	J. Tennvall et al., Cancer (Dec. 15, 1997), Vol. 80, No. 12 (Suppl.) pp. 2411-2418
	M.J.P.G. Van Kroonenburgh and E.K.J. Pauwels, Nucl. Med. Commun., (1988) Vol. 9, pp. 919-920
	G. Wallukat et al, New England J. Med., (Nov. 28, 2002), Vol. 347, No. 22, p. 1806
	8. Yazdani et al, American Heart J., (August 1998), Vol. 136 (2) pp. 357-61

EXAMINER	V~	DATE CONSIDERED	12/12/07

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)